The current state of niacin in cardiovascular disease prevention: A systematic review and meta-regression

Journal of the American College of Cardiology

Volumn 61, Issue 4, 2013, Pages 440-446

  Lavigne, Paul M ^a   Karas, Richard H ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; HDL cholesterol; lipids; niacin

Indexed keywords

CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG USE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MONOTHERAPY; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 84872679028     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.10.030     Document Type: Article

References (50)

1. Adult Treatment Panel III Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation 106 2002 3143 3421
2. S.M. Grundy, J.I. Cleeman, C.N.B. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
3. S.C. Smith, E.J. Benjamin, R.O. Bonow AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association J Am Coll Cardiol 58 2011 2432 2446
4. C. Baigent, A. Keech, P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
5. C. Baigent, L. Blackwell, J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
6. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
7. C. Cannon, E. Braunwald, C. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
8. J.C. LaRosa, S.M. Grundy, D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
9. J. de Lemos, M. Blazing, S. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
10. T. Pedersen, O. Faergeman, J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction JAMA 294 2005 2437 2445
11. J. Armitage, L. Bowman, K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
12. V.S. Kamanna, M.L. Kashyap Mechanism of action of niacin on lipoprotein metabolism Curr Atheroscler Rep 2 2000 36 46
13. V.S. Kamanna, M.L. Kashyap Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 100 2007 S53 S61
14. V.S. Kamanna, M.L. Kashyap Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
15. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
16. B. Brown, X. Zhao, A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
17. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
18. A.J. Taylor, H.J. Lee, L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
19. A. Taylor, T. Villines, E. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
20. T.C. Villines, E.J. Stanek, P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2010 2721 2726
21. J.M.S. Lee, M.D. Robson, L.-M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
22. W.E. Boden, J.L. Probstfield, T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
23. E. Bruckert, J. Labreuche, P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
24. J.K. Duggal, M. Singh, N. Attri Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease J Cardiovasc Pharmacol Ther 15 2010 158 166
25. G. Brown, J. Albers, L. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
26. J.R. Guyton, B.G. Brown, S. Fazio, A. Polis, J.E. Tomassini, A.M. Tershakovec Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia J Am Coll Cardiol 51 2008 1564 1572
27. A.R. Jadad, R.A. Moore, D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
28. E.J. Whitney, R.A. Krasuski, B.E. Personius, J.E. Michalek, A.M. Maranian, M.W. Kolasa A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
29. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, M.E. Sanmarco, S.P. Azen, L. Cashin-Hemphill Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240
30. L.A. Carlson, G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
31. J.P. Kane, M.J. Malloy, T.A. Ports, N.R. Phillips, J.C. Diehl, R.J. Havel Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007 3012
32. J.C. Larosa, J. He, S. Vupputuri, M.S. Headings Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
33. H. Jafri, A.A. Alsheikh-Ali, R.H. Karas Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk Ann Intern Med 153 2010 800 808
34. T. Gordon, W. Castelli, M. Hjortland, W. Kannel, T. Daber High density lipoprotein as a protective factor against coronary heart disease The Framingham Study Am J Med 62 1977 707 714
35. P. Wilson, R. Garrison, W. Castelli, M. Feinleib, P. McNamara, W. Kannel Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols Am J Cardiol 46 1980 649 654
36. W. Castelli, R. Garrison, P. Wilson, R. Abbott, S. Kalousdian, W. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels The Framingham Study JAMA 256 1986 2835 2838
37. D.J. Gordon, J.L. Probstfield, R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease Four prospective American studies Circulation 79 1989 8 15
38. J.T. Kuvin, D.M. Dave, K.A. Sliney Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease Am J Cardiol 98 2006 743 745
39. J.E. Digby, E. McNeill, O.J. Dyar, V. Lam, D.R. Greaves, R.P. Choudhury Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin Atherosclerosis 209 2010 89 95
40. A. Linke, M. Sonnabend, M. Fasshauer Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance Atherosclerosis 205 2009 207 213
41. J.M.S. Lee, M.D. Robson, L.-M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
42. B.J. Wu, L. Yan, F. Charlton, P. Witting, P.J. Barter, K.-A. Rye Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids Arterioscler Thromb Vasc Biol 30 2010 968 975
43. M. Lukasova, C. Malaval, A. Gille, J. Kero Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109a expressed by immune cells J Clin Invest 121 2011 1163 1173
44. E. Holzhäuser, C. Albrecht, Q. Zhou Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities J Cardiovasc Pharmacol 57 2011 447 454
45. Roche Inc Roche Provides Update on Phase III Study of Dalcetrapib [press release] http://www.roche.com/media/media-releases/med-cor-2012-05-07.htm May 2012 Accessed May 23, 2012
46. E.A. Stein, E.S.G. Stroes, G. Steiner Safety and tolerability of dalcetrapib Am J Cardiol 104 2009 82 91
47. B.F. Voight, G.M. Peloso, M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 6736 2012 1 9
48. A.A. Alsheikh-Ali, R.H. Karas The safety of niacin in the US Food and Drug Administration adverse event reporting database Am J Cardiol 101 2008 9B 13B
49. A.A. Alsheikh-Ali, R.H. Karas Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system) Am J Cardiol 99 2007 379 381
50. C.M. Ballantyne, M.H. Davidson, J.M. McKenney, L.H. Keller, D.R. Bajorunas, R.H. Karas Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study J Clin Lipidol 2 2008 79 90